RPRX

SEC source: 0001814876-25-000005 · wk-form4_1763589210.xml · nonDerivative · entry 2

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Plan reported

Ownership: Indirect · TPC RP EPA1 LLC

Disclosed balance after: 54,760

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001814876-25-000005 · wk-form4_1763589210.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: Plan reported

Ownership: Indirect · By TPC RP 2021, LLC

Disclosed balance after: 724,156

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001838139-25-000004 · wk-form4_1762550186.xml · derivative · entry 4

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sandy Lamm LLC

Disclosed balance after: 247,412

Underlying: Class A Ordinary Shares · 160,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001838139-25-000004 · wk-form4_1762550186.xml · nonDerivative · entry 2

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sandy Lamm LLC

Disclosed balance after: 206,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.

SEC source: 0001814899-25-000003 · wk-form4_1762550308.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 58,510

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001814238-25-000003 · wk-form4_1762550287.xml · nonDerivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 658,510

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001507678-25-000010 · wk-form4_1762550365.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 940,955

F1 · acquired: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001814876-25-000003 · wk-form4_1762550332.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · TPC RP EPA1 LLC

Disclosed balance after: 58,510

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001838139-25-000004 · wk-form4_1762550186.xml · nonDerivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,882

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001683607-25-000004 · wk-form4_1759265653.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,165

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · nonDerivative · entry 2

Norden Gregory · CIK 0001405104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,848

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.10 to $36.40 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · derivative · entry 9

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 85,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000105 · wk-form4_1754686796.xml · derivative · entry 13

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 692,701

Underlying: Class A Ordinary Shares · 600,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000104 · wk-form4_1754686694.xml · derivative · entry 7

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · By TPC ICAI, LLC

Disclosed balance after: 43,350

Underlying: Class A Ordinary Shares · 10,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000101 · wk-form4_1754686370.xml · derivative · entry 4

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Indirect · By Sandy Lamm LLC

Disclosed balance after: 263,412

Underlying: Class A Ordinary Shares · 30,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · derivative · entry 3

Norden Gregory · CIK 0001405104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 144,660 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents limited partnership interests in RPI US Partners 2019, LP ("RPI US LP Interests"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value.

SEC source: 0001802768-25-000107 · wk-form4_1754944552.xml · nonDerivative · entry 1

Norden Gregory · CIK 0001405104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with the exchange.

SEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 52,342

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000102 · wk-form4_1754686485.xml · nonDerivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 652,342

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000105 · wk-form4_1754686796.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 904,396

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000104 · wk-form4_1754686694.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · TPC RP EPA1 LLC

Disclosed balance after: 52,342

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000101 · wk-form4_1754686370.xml · nonDerivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,256

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000090 · wk-form4_1754009123.xml · nonDerivative · entry 2

WEATHERMAN ELIZABETH H · CIK 0001188681 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,558

F2 · shares: Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000090 · wk-form4_1754009123.xml · nonDerivative · entry 1

WEATHERMAN ELIZABETH H · CIK 0001188681 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,752

F1 · shares: Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000088 · wk-form4_1754008916.xml · nonDerivative · entry 2

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,558

F2 · shares: Reflects a pro-rated annual equity award of restricted stock units under the Plan that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000088 · wk-form4_1754008916.xml · nonDerivative · entry 1

Ho Carole · CIK 0001724605 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,752

F1 · shares: Reflects an initial equity award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000077 · wk-form4_1751317557.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,324

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000075 · wk-form4_1751317462.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,118

F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

SEC source: 0001802768-25-000065 · wk-form4_1747774253.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote (1)(2)

Disclosed balance after: 1,944,471

Underlying: Class A Ordinary Shares · 1,944,471 shares

Expires not disclosed

F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

SEC source: 0001802768-25-000071 · wk-form4_1747774487.xml · derivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote (1)(2)

Disclosed balance after: 1,238,789

Underlying: Class A Ordinary Shares · 1,238,789 shares

Expires not disclosed

F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

SEC source: 0001802768-25-000069 · wk-form4_1747774436.xml · derivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote (1)(2)

Disclosed balance after: 1,356,528

Underlying: Class A Ordinary Shares · 1,356,528 shares

Expires not disclosed

F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

SEC source: 0001802768-25-000067 · wk-form4_1747774366.xml · derivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote (1)(2)

Disclosed balance after: 1,807,277

Underlying: Class A Ordinary Shares · 1,807,277 shares

Expires not disclosed

F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · derivative · entry 14

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By PL RPH Holdings, LLC

Disclosed balance after: 857,138

Underlying: Class A Ordinary Shares · 857,138 shares

Expires not disclosed

F4 · shares: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.exercise_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · derivative.exercise_date: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.expiration_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · derivative.expiration_date: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F3 · derivative.underlying_shares: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F4 · balance_after: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

F4 · ownership.nature: Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · derivative · entry 13

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By PL RPH Holdings, LLC

Disclosed balance after: 13,356,742

Underlying: Class A Ordinary Shares · 13,356,742 shares

Expires not disclosed

F2 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F3 · derivative.exercise_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · derivative.expiration_date: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · derivative.underlying_shares: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F3 · balance_after: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

F2 · ownership.nature: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F3 · ownership.nature: Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion.

SEC source: 0001802768-25-000063 · wk-form4_1747774159.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 882,495

F1 · kind: Represents the transfer to the Reporting Person by the RP Management Equity Incentive Plan Trust of Class A Ordinary Shares for no consideration.

SEC source: 0001802768-25-000057 · wk-form4_1747257126.xml · nonDerivative · entry 1

Norden Gregory · CIK 0001405104 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,688

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000055 · wk-form4_1747257065.xml · nonDerivative · entry 1

LOVE TED W · CIK 0001188919 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,848

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000053 · wk-form4_1747256988.xml · nonDerivative · entry 1

HODGSON DAVID C · CIK 0001193346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,328

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the reporting person are held by him solely for the benefit of General Atlantic Service Company, L.P. The reporting person disclaims beneficial ownership of the restricted stock units in the underlying shares.

SEC source: 0001802768-25-000049 · wk-form4_1747256848.xml · nonDerivative · entry 1

DESOUZA ERROL B · CIK 0001213895 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,352

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000051 · wk-form4_1747256918.xml · nonDerivative · entry 1

Fernandez Henry A · CIK 0001416750 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,260

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000047 · wk-form4_1747256775.xml · nonDerivative · entry 1

Coric Vlad · CIK 0001704317 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,798

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000045 · wk-form4_1747256688.xml · nonDerivative · entry 1

Bassler Bonnie L · CIK 0001683607 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,054

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000061 · wk-form4_1747345286.xml · nonDerivative · entry 1

Engelbert Catherine M. · CIK 0001796439 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,128

F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder.

SEC source: 0001802768-25-000043 · wk-form4_1747256539.xml · derivative · entry 2

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 867,180 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of Class B ordinary shares ("Class B Shares") of Royalty Pharma Holdings Ltd ("RPH") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a).

F2 · derivative.exercise_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F3 · balance_after: Reflects the exempt transfer pursuant to Rule 16a-13 of Class B Shares from the reporting person and the GST-Exempt Legorreta 2020 Family Trust to PL RPH AIV, LLC, which is solely beneficially owned by the reporting person. The Class B Shares transferred by the reporting person and the GST-Exempt Legorreta 2020 Family Trust were originally received in exempt pro rata distributions pursuant to Rule 16a-9(a) and the gift transaction reported in this filing.

SEC source: 0001802768-25-000043 · wk-form4_1747256539.xml · derivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 867,180 shares

Expires not disclosed

F1 · kind: Reflects an exempt gift for no consideration of Class B ordinary shares ("Class B Shares") of Royalty Pharma Holdings Ltd ("RPH") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a).

F2 · derivative.exercise_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion.

SEC source: 0001802768-25-000037 · wk-form4_1746825335.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 48,646

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000035 · wk-form4_1746825246.xml · nonDerivative · entry 1

Hite Christopher · CIK 0001814238 · EVP & Vice Chairman

10b5-1 filing: No plan indicated

Ownership: Indirect · By SCH Investment Partners LLC

Disclosed balance after: 648,646

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000039 · wk-form4_1746825503.xml · nonDerivative · entry 1

Legorreta Pablo G. · CIK 0001507678 · Director · CEO, Chairman of the Board

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 352,147

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000033 · wk-form4_1746825035.xml · nonDerivative · entry 1

Coyne Terrance P. · CIK 0001814876 · EVP & CFO

10b5-1 filing: No plan indicated

Ownership: Indirect · TPC RP EPA1 LLC

Disclosed balance after: 48,646

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

SEC source: 0001802768-25-000031 · wk-form4_1746824860.xml · nonDerivative · entry 1

Urist Marshall · CIK 0001838139 · EVP, Research & Investments

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,151

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.